Consensus guidelines recommend a number of screening examinations for survivors following allogeneic hematopoietic cell transplantation (HCT) but the frequency of detecting abnormal findings is unknown. We reviewed medical records of 118 patients who had comprehensive, standardized evaluations at one year after allogeneic HCT at Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance. Abnormal findings were common, including moderate-severe pulmonary dysfunction (16%), fasting hyperlipidemia (56%), osteopenia (52%), osteoporosis (6%), and active chronic graft-versus-host disease (64%). Recurrent malignancy (4%) and chronic graft-versus-host disease (29%) were detected in previously unsuspected cases. Only 3% of patients had no abnormal findings. We conclude that comprehensive evaluation at one year after allogeneic HCT detects a high frequency of medical problems. Longer follow-up will be required to determine whether early detection and intervention affects late morbidity and mortality.
BackgroundND2 in Ho Chi Minh City is currently the only public center that performs PLT in Southern Vietnam. In 2005, the first PLT was successfully performed, with support from Belgian experts. This study reviews the implementation of PLT at our center and evaluates the results and challenges.MethodsImplementation of PLT at ND2 required medico‐surgical team building and extensive improvement of hospital facilities. Records of 13 transplant recipients from 2005 to 2020 were studied retrospectively. Short‐ and long‐term complications, as well as the survival rates, were reported.ResultsThe mean follow‐up time was 8.3 ± 5.7 years. Surgical complications included one case of hepatic artery thrombosis that was successfully repaired, one case of colon perforation resulting in death from sepsis, and two cases of bile leak that were drained surgically. PTLD was observed in five patients, of whom three died. There were no cases of retransplantation. The 1‐year, 5‐year, and 10‐year patient survival rates were 84.6%, 69.2%, and 69.2%, respectively. There were no cases of complication or death among the donors.ConclusionLiving‐donor PLT was developed at ND2 for providing a life‐saving treatment to children with end‐stage liver disease. Early surgical complication rate was low, and the patient survival rate was satisfactory at 1 year. Long‐term survival decreased considerably due to PTLD. Future challenges include surgical autonomy and improvement of long‐term medical follow‐up with a particular emphasis on prevention and management of Epstein–Barr virus‐related disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.